Michael McBreen was named Chief Commercial Officer of Integra Lifesciences Holdings Corp. As of November 15, 2026, Integra Lifesciences Holdings Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 5, 2026, naming 1 appointment (Form 8-K, May 5, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Integra Lifesciences Holdings Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Integra Lifesciences Holdings Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-05. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Integra Lifesciences Holdings Corp files it.
Also on the record for Integra Lifesciences Holdings Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G, by Invesco Ltd. | 5.4% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by PARADIGM CAPITAL MANAGEMENT INC/NY | — | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.02% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by PARADIGM CAPITAL MANAGEMENT INC/NY | 5.2% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Fuller & Thaler Asset Management, Inc. | 4.67% of the class | 5%+ stakes | Source |
| November 6, 2025 | Stake report, Schedule 13G/A, by Invesco Ltd. | 4.5% of the class | 5%+ stakes | Source |
| August 5, 2025 | Stake report, Schedule 13G/A, by Morgan Stanley | 4.3% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 13.2% of the class | 5%+ stakes | Source |
| July 9, 2025 | Stake report, Schedule 13G/A, by Rubric Capital Management LP | 9.46% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Integra Lifesciences Holdings Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Integra Lifesciences Holdings Corp and the records around it.
Integra Lifesciences Holdings Corp elsewhere on the record
Companies that share a holder
- PARADIGM CAPITAL MANAGEMENT INC/NY also filed stake reports on 7 other companies: ACCENDRA HEALTH INC/VA/ (Nov 2026), BUILD-A-BEAR WORKSHOP INC (Aug 2026), NN INC (Feb 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- Fuller & Thaler Asset Management, Inc. also filed stake reports on 35 other companies: COLLEGIUM PHARMACEUTICAL, INC (Aug 2026), Graphic Packaging Holding Co (Aug 2026), Primoris Services Corp (Aug 2026)
Watch Integra Lifesciences Holdings Corp
Get an email when Integra Lifesciences Holdings Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Integra Lifesciences Holdings Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Integra Lifesciences Holdings Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Integra Lifesciences Holdings Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-05 | In | Chief Commercial Officer | 8-K, 2026-05-05 |
Who leads Integra Lifesciences Holdings Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Commercial Officer: Michael McBreen, appointed (filed 2026-05-05).
New leaders reset buying decisions — get the Full Report on Integra Lifesciences Holdings Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Commercial Officer at Integra Lifesciences Holdings Corp, with the record behind each one.
Find candidates like Chief Commercial Officer at Integra Lifesciences Holdings CorpEvery change, in the filing's words
Appointed: Michael McBreen, Chief Commercial Officer
On May 5, 2026, the Company also announced the appointment of Michael McBreen, the Company's Executive Vice President, President, Codman Specialty Surgical, as Chief Commercial Officer effective as of the Start Date.
- Appointment of Dr. Stuart Essig as President and Chief Executive Officer On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").
- Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
- Dr. Essig, 64, has served as Chairman of the Board since January 2012 and will continue to serve in such role following his appointment as President and Chief Executive Officer.
- Prior to serving as Chairman, he served as the Company's Chief Executive Officer and as a director from 1997 through 2012 and as the Company's President from 1997 until 2010.
- From February 2024 to June 2025, he served as the Executive Chairman of the Board.
- Prior to joining the Company, he acted as the managing director in mergers and acquisitions for the medical technology practice at Goldman, Sachs & Co. He currently serves as managing director of Prettybrook Partners, LLC, a family office dedicated to investing in healthcare companies, which he cofounded in 2012.
Tools for this story
Each opens in a new tab, filled in for Integra Lifesciences Holdings Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
